Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: Primary Results from the Phase 3 AURIGA Study

Author(s):

Dr. Rafael Fonseca presents the primary results of the phase 3 AURIGA study, which demonstrates the significant improvement in MRD-negative conversion and progression-free survival with subcutaneous daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in newly diagnosed multiple myeloma post-transplant, shared at the 2024 International Myeloma Society Annual Meeting.

Disclaimers:

0:48 - Repotrectinib was approved in the US in 2023 with a line agnostic indication. Its market authorization application was validated by EMA in 2024, but it is not yet approved in Europe.
5:22 - 71% in the repotrectinib naive population, not 51%
8:15 - "Overall we see a potential ROS1 inhibitor that we can qualify as second generation because it's the G3022R resistance mutation and with a very favorable safety profile..." Speaker intended to reference G2032R mutation.